Transcriptomic Analysis of the Claudin Interactome in Malignant Pleural Mesothelioma: Evaluation of the Effect of Disease Phenotype, Asbestos Exposure, and CDKN2A Deletion Status
暂无分享,去创建一个
[1] Paschalis-Adam Molyvdas,et al. Transcriptional over-expression of chloride intracellular channels 3 and 4 in malignant pleural mesothelioma , 2015, Comput. Biol. Chem..
[2] K. Gourgoulianis,et al. Computational genomic analysis of PARK7 interactome reveals high BBS1 gene expression as a prognostic factor favoring survival in malignant pleural mesothelioma. , 2015, American journal of physiology. Lung cellular and molecular physiology.
[3] P. Gosset,et al. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. , 2015, Annals of diagnostic pathology.
[4] C. Lim,et al. Mesothelial cells in tissue repair and fibrosis , 2015, Front. Pharmacol..
[5] M. Vyberg,et al. The established and future biomarkers of malignant pleural mesothelioma. , 2015, Cancer treatment reviews.
[6] V. Antony,et al. Pleural mesothelial cells in pleural and lung diseases. , 2015, Journal of thoracic disease.
[7] J. Creaney,et al. Discovery of new biomarkers for malignant mesothelioma , 2015, Current Pulmonology Reports.
[8] Qiang Li,et al. Use of Proteins as Biomarkers and Their Role in Carcinogenesis , 2015, Journal of Cancer.
[9] N. Pavlakis,et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales , 2014, British Journal of Cancer.
[10] E. Taioli,et al. Women with malignant pleural mesothelioma have a threefold better survival rate than men. , 2014, The Annals of thoracic surgery.
[11] S. Amasheh,et al. Tight junction physiology of pleural mesothelium , 2014, Front. Physiol..
[12] G. Pinkus,et al. Claudin‐4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology , 2014, Cancer cytopathology.
[13] M. Fromm,et al. Laurate Permeates the Paracellular Pathway for Small Molecules in the Intestinal Epithelial Cell Model HT-29/B6 via Opening the Tight Junctions by Reversible Relocation of Claudin-5 , 2014, Pharmaceutical Research.
[14] M. Fromm,et al. Erratum to: Laurate Permeates the Paracellular Pathway for Small Molecules in the Intestinal Epithelial Cell Model HT-29/B6 via Opening the Tight Junctions by Reversible Relocation of Claudin-5 , 2014, Pharmaceutical Research.
[15] M. Fromm,et al. Comparative analysis of theophylline and cholera toxin in rat colon reveals an induction of sealing tight junction proteins , 2014, Pflügers Archiv - European Journal of Physiology.
[16] W. Thomas,et al. Malignant pleural mesothelioma incidence and survival in the Republic of Ireland 1994-2009. , 2014, Cancer epidemiology.
[17] U. Manne,et al. The Chemokine CXCL8 in Carcinogenesis and Drug Response , 2013, ISRN oncology.
[18] M. Kushima,et al. Claudin-4 as a Marker for Distinguishing Malignant Mesothelioma From Lung Carcinoma and Serous Adenocarcinoma , 2013, International journal of surgical pathology.
[19] N. Ordóñez. Value of claudin-4 immunostaining in the diagnosis of mesothelioma. , 2013, American journal of clinical pathology.
[20] Y. C. Lee,et al. The continual search for ideal biomarkers for mesothelioma: the hurdles. , 2013, Journal of thoracic disease.
[21] K. Gourgoulianis,et al. Gene expression profile of aquaporin 1 and associated interactors in malignant pleural mesothelioma. , 2013, Gene.
[22] M. Copin,et al. M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo. , 2013, In vivo.
[23] Christie S. Chang,et al. The BioGRID interaction database: 2013 update , 2012, Nucleic Acids Res..
[24] Ralf Herwig,et al. The ConsensusPathDB interaction database: 2013 update , 2012, Nucleic Acids Res..
[25] Stephen A. Williams,et al. Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool , 2012, PloS one.
[26] Duane H. Hamilton,et al. Influence of IL-8 on the epithelial-mesenchymal transition and the tumor microenvironment. , 2012, Future oncology.
[27] P. Rascoe,et al. Molecular pathogenesis of malignant mesothelioma , 2012, Expert Reviews in Molecular Medicine.
[28] F. Gemignani,et al. A review of transcriptome studies combined with data mining reveals novel potential markers of malignant pleural mesothelioma. , 2012, Mutation research.
[29] K. Gourgoulianis,et al. Matrix metalloproteinases 2 and 9 increase permeability of sheep pleura in vitro , 2012, BMC Physiology.
[30] K. Kiura,et al. Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma , 2012, Cancer science.
[31] Xiaowen Pang,et al. S100B protein as a possible participant in the brain metastasis of NSCLC , 2012, Medical Oncology.
[32] J. Dwyer,et al. Jumping the barrier: VE‐cadherin, VEGF and other angiogenic modifiers in cancer , 2011, Biology of the cell.
[33] B. Christensen,et al. Epigenomics in Environmental Health , 2011, Front. Gene..
[34] Y. Soini. Claudins in lung diseases , 2011, Respiratory research.
[35] M. Fromm,et al. Tight junction proteins contribute to barrier properties in human pleura , 2011, Respiratory Physiology & Neurobiology.
[36] B. Davidson. The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma , 2011, Cytopathology : official journal of the British Society for Clinical Cytology.
[37] Damian Szklarczyk,et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..
[38] S. Milatz,et al. Claudin-3 acts as a sealing component of the tight junction for ions of either charge and uncharged solutes. , 2010, Biochimica et biophysica acta.
[39] N. Reinmuth,et al. Current data on predictive markers for anti-angiogenic therapy in thoracic tumours , 2010, European Respiratory Journal.
[40] George M Yousef,et al. Personalized Medicine: Marking a New Epoch in Cancer Patient Management , 2010, Molecular Cancer Research.
[41] D. Waller,et al. Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile? , 2010, The Annals of thoracic surgery.
[42] P. Morin,et al. The claudins , 2009, Genome Biology.
[43] Dean A Fennell,et al. Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. , 2009, Cancer research.
[44] A. Musk,et al. Predicting survival in malignant mesothelioma , 2009, European Respiratory Journal.
[45] J. Schleutker,et al. Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. , 2009, The Journal of urology.
[46] Sung-Liang Yu,et al. Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. , 2009, American journal of respiratory and critical care medicine.
[47] J. Gavard. Breaking the VE‐cadherin bonds , 2008, FEBS letters.
[48] D. Waugh,et al. The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.
[49] Ralf Herwig,et al. ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..
[50] J. Gutkind,et al. VE-cadherin and claudin-5: it takes two to tango , 2008, Nature Cell Biology.
[51] F. Orsenigo,et al. Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5 , 2008, Nature Cell Biology.
[52] K. Friedrich,et al. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. , 2008, Cancer research.
[53] T. Nakano. Current therapies for malignant pleural mesothelioma , 2008, Environmental health and preventive medicine.
[54] S. Lonardi,et al. Claudin‐4 in mesothelioma diagnosis , 2007, Histopathology.
[55] B. Murer,et al. Claudin 4 identifies a wide spectrum of epithelial neoplasms and represents a very useful marker for carcinoma versus mesothelioma diagnosis in pleural and peritoneal biopsies and effusions , 2007, Virchows Archiv.
[56] I. Shih,et al. The diagnostic role of claudins in serous effusions. , 2007, American journal of clinical pathology.
[57] I. Shih,et al. Gene Expression Signatures Differentiate Ovarian/Peritoneal Serous Carcinoma from Diffuse Malignant Peritoneal Mesothelioma , 2006, Clinical Cancer Research.
[58] A. Olshen,et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.
[59] Y. Soini,et al. Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura , 2006, Journal of Clinical Pathology.
[60] Michael C. Wendl,et al. Argonaute—a database for gene regulation by mammalian microRNAs , 2005, BMC Bioinformatics.
[61] B. Robinson,et al. Advances in malignant mesothelioma. , 2005, The New England journal of medicine.
[62] J. Schulzke,et al. Contribution of claudin-5 to barrier properties in tight junctions of epithelial cells , 2005, Cell and Tissue Research.
[63] R. Harpio,et al. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. , 2004, Clinical biochemistry.
[64] M. Claeyssens,et al. A hydrophobic platform as a mechanistically relevant transition state stabilising factor appears to be present in the active centre of all glycoside hydrolases , 2003, FEBS letters.
[65] Torsten Schöneberg,et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells , 2002, Journal of Cell Science.
[66] V. Antony,et al. Polar production of interleukin-8 by mesothelial cells promotes the transmesothelial migration of neutrophils: role of intercellular adhesion molecule-1. , 2001, The Journal of infectious diseases.
[67] M. Osanai,et al. Claudins in cancer: bench to bedside , 2016, Pflügers Archiv - European Journal of Physiology.
[68] Abderrahman Ouban,et al. Claudins in human cancer: a review. , 2010, Histology and histopathology.
[69] Erika Garay,et al. Chapter 6 - Regulation of Claudins by Posttranslational Modifications and Cell-Signaling Cascades , 2010 .
[70] P. Morin,et al. Chapter 13 - Claudins in Cancer Biology , 2010 .
[71] David J Sugarbaker,et al. Tumorigenesis and Neoplastic Progression Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling , 2005 .
[72] T. Barrette,et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.
[73] D. Lancet,et al. Human Gene-Centric Databases at the Weizmann Institute of Science: GeneCards, UDB, CroW 21 and HORDE , 2003, Nucleic Acids Res..
[74] M. Ward,et al. Inhibition of interleukin-8 reduces human malignant pleural mesothelioma propagation in nude mouse model. , 1999, Oncology research.